CA
HAE icon

Continuum Advisory’s Haemonetics HAE Stock Holding History

Continuum Advisory’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$1.59K – 885
2025
Q1 		$1.59K Sell
25
-3
-11% -$204 ﹤0.01% 1425
2024
Q4 		$2.19K Buy
28
+6
+27% +$482 ﹤0.01% 1391
2024
Q3 		$2K Sell
22
-9
-29% -$727 ﹤0.01% 1429
2024
Q2 		$2.56K Hold
31
– – ﹤0.01% 1234
2024
Q1 		$2.87K Buy
+31
New +$2.43K ﹤0.01% 1195

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Continuum Advisory's HAE Position: Q2 2025 in Review

Continuum Advisory sold out of Haemonetics (HAE) in Q2 2025, closing a stake of 25 shares — an estimated $1.59K sold.

Continuum Advisory first reported a position in HAE in Q1 2024 and held it in 5 quarters. The position peaked at $2.87K in Q1 2024. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

  • Continuum Advisory reported no remaining Haemonetics position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 25 Haemonetics shares in Q2 2025, an estimated $1.59K.
  • Continuum Advisory first reported a position in Haemonetics in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Haemonetics position peaked at $2.87K in Q1 2024.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.